Emerald Health Therapeutics, Inc. (EMHTF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Emerald Health Therapeutics, Inc. (EMHTF), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 40/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 18 Mar 2026Emerald Health Therapeutics, Inc. (EMHTF) Sağlık ve Boru Hattı Genel Bakışı
Emerald Health Therapeutics, Inc. is a Canadian cannabis company involved in the production, distribution, and sale of recreational and medical cannabis products. Operating as a subsidiary of Skye Bioscience, Inc., Emerald Health offers a range of cannabis products, facing strong competition in the evolving Canadian cannabis market.
Yatırım Tezi
Investing in Emerald Health Therapeutics, Inc. (EMHTF) presents a high-risk, high-reward scenario. The company's negative profit margin of -411.9% and gross margin of -66.7% indicate significant financial challenges. EMHTF operates in the competitive Canadian cannabis market, where profitability has been elusive for many players. A potential growth catalyst lies in the expansion of its product lines and market reach within Canada. However, investors should closely monitor EMHTF's financial performance and its ability to achieve sustainable profitability. The company's status as a subsidiary of Skye Bioscience, Inc. adds another layer of complexity, as its strategic direction may be influenced by its parent company. Given the current financial metrics and competitive landscape, EMHTF requires a turnaround strategy to deliver value to investors.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Negative Profit Margin: Emerald Health Therapeutics has a profit margin of -411.9%, indicating substantial losses.
- Negative Gross Margin: The company's gross margin is -66.7%, reflecting challenges in cost management and pricing.
- P/E Ratio: Emerald Health Therapeutics has a P/E ratio of -0.27, signaling that the company is currently unprofitable.
- Subsidiary Status: Emerald Health Therapeutics operates as a subsidiary of Skye Bioscience, Inc. since November 10, 2022.
- Beta: The company has a beta of 0.63, suggesting lower volatility compared to the overall market.
Rakipler & Benzerleri
Güçlü Yönler
- Diverse product portfolio including dried cannabis, pre-rolls, oral sprays, and oils.
- Established brands such as SYNC Wellness and Emerald.
- Distribution network within the Canadian cannabis market.
- Subsidiary of Skye Bioscience, Inc., providing potential access to resources and expertise.
Zayıflıklar
- Negative profit and gross margins indicating financial struggles.
- Dependence on the Canadian cannabis market.
- Intense competition from other licensed producers.
- Operating as a subsidiary may limit strategic autonomy.
Katalizörler
- Upcoming: Potential regulatory changes in the Canadian cannabis market that could benefit licensed producers.
- Ongoing: Expansion of product lines to include new and innovative cannabis products.
- Ongoing: Geographic expansion within Canada to reach new markets.
- Ongoing: Focus on the higher-margin medical cannabis market.
- Ongoing: Strategic partnerships and acquisitions to expand capabilities.
Riskler
- Ongoing: Oversupply and price compression in the Canadian cannabis market.
- Ongoing: Changing regulations and consumer preferences.
- Potential: Competition from illicit cannabis producers.
- Ongoing: Potential for further financial losses due to negative profit and gross margins.
- Potential: Dependence on the Canadian cannabis market.
Büyüme Fırsatları
- Expansion of Product Lines: Emerald Health can expand its product offerings to include new and innovative cannabis products, such as edibles, concentrates, and topicals. The market for these products is growing rapidly, driven by consumer demand for alternative consumption methods. By introducing new products, Emerald Health can attract new customers and increase its market share. The timeline for this growth opportunity is immediate, as the company can begin developing and launching new products in the near term. Success depends on effective product development and marketing strategies.
- Geographic Expansion within Canada: Emerald Health can expand its distribution network to reach new markets within Canada. This could involve partnering with retailers in provinces where the company currently has limited presence or establishing its own retail locations. Geographic expansion would allow Emerald Health to increase its sales volume and diversify its revenue streams. The timeline for this growth opportunity is medium-term, as it may take time to secure partnerships and establish new retail locations. Success depends on effective market research and strategic partnerships.
- Focus on Medical Cannabis Market: Emerald Health can focus on the medical cannabis market, which offers higher margins and greater regulatory certainty compared to the recreational market. This could involve developing cannabis-based pharmaceuticals or partnering with healthcare providers to offer cannabis-based treatments. The medical cannabis market is growing rapidly, driven by increasing awareness of the therapeutic benefits of cannabis. The timeline for this growth opportunity is long-term, as it may take time to develop new pharmaceuticals and secure regulatory approvals. Success depends on scientific research and clinical trials.
- Strategic Partnerships and Acquisitions: Emerald Health can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. This could involve partnering with other cannabis companies, technology companies, or healthcare providers. Strategic partnerships and acquisitions can provide access to new technologies, markets, and expertise. The timeline for this growth opportunity is ongoing, as the company can continuously explore potential partnerships and acquisitions. Success depends on effective due diligence and integration.
- Development of Proprietary Cannabis Strains: Emerald Health can invest in research and development to develop proprietary cannabis strains with unique characteristics, such as higher potency, unique flavor profiles, or specific therapeutic benefits. Proprietary strains can provide a competitive advantage and allow the company to differentiate its products. The timeline for this growth opportunity is long-term, as it may take time to develop and stabilize new strains. Success depends on scientific expertise and effective breeding programs.
Fırsatlar
- Expansion into new product categories such as edibles and concentrates.
- Geographic expansion within Canada.
- Focus on the higher-margin medical cannabis market.
- Strategic partnerships and acquisitions to expand capabilities.
Tehditler
- Oversupply and price compression in the Canadian cannabis market.
- Changing regulations and consumer preferences.
- Competition from illicit cannabis producers.
- Potential for further financial losses.
Rekabet Avantajları
- Brand recognition through SYNC Wellness, fuse, Emerald, and Souvenir brands.
- Established distribution network in the Canadian cannabis market.
- Proprietary formulations for oral sprays and nano emulsion shots.
- Access to a range of cannabis strains and product formats.
EMHTF Hakkında
Emerald Health Therapeutics, Inc. was initially founded as T-Bird Pharma Inc. before rebranding in June 2015 to reflect its focus on the burgeoning cannabis industry. Headquartered in Vancouver, Canada, the company cultivates, processes, and distributes a variety of cannabis products, including dried cannabis strains, pre-rolled cannabis, oral sprays, nano emulsion shots, and cannabis oil products. These products are marketed under several brands, including SYNC Wellness, fuse, Emerald, and Souvenir. Emerald Health aims to cater to both the recreational and medical cannabis markets in Canada. However, as of November 10, 2022, Emerald Health Therapeutics operates as a subsidiary of Skye Bioscience, Inc., marking a significant shift in its corporate structure. The company's evolution reflects the dynamic nature of the cannabis industry, with Emerald Health adapting its strategy to navigate regulatory changes and evolving consumer preferences. Its product portfolio is designed to appeal to a broad spectrum of cannabis users, from those seeking traditional dried flower to those preferring more innovative consumption methods like oral sprays and nano emulsion shots.
Ne Yaparlar
- Produces dried cannabis strains for recreational and medical use.
- Manufactures pre-rolled cannabis products for convenient consumption.
- Develops and sells oral sprays containing cannabis extracts.
- Offers nano emulsion shots for rapid cannabis absorption.
- Produces cannabis oil products for various applications.
- Markets its products under the SYNC Wellness, fuse, Emerald, and Souvenir brands.
- Distributes cannabis products through various channels in Canada.
İş Modeli
- Cultivates and processes cannabis plants.
- Manufactures a range of cannabis products.
- Distributes and sells products through retail channels and partnerships.
- Generates revenue from the sale of cannabis products to recreational and medical consumers.
Sektör Bağlamı
Emerald Health Therapeutics operates within the Canadian cannabis industry, which has experienced significant growth since legalization but also faces challenges such as oversupply, regulatory hurdles, and intense competition. The market includes both recreational and medical cannabis segments, with evolving consumer preferences for different product formats. Key competitors include other licensed producers who are vying for market share. Emerald Health's success depends on its ability to differentiate its products, manage costs effectively, and navigate the complex regulatory landscape. The Canadian cannabis market is projected to continue growing, driven by increasing consumer acceptance and the development of new products and distribution channels.
Kilit Müşteriler
- Recreational cannabis consumers in Canada.
- Medical cannabis patients with prescriptions.
- Retail partners who sell Emerald Health's products.
- Wholesale distributors of cannabis products.
Finansallar
Grafik & Bilgi
Emerald Health Therapeutics, Inc. (EMHTF) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 Mar 2020
-
Stocks That Hit 52-Week Lows On Friday
· 28 Şub 2020
-
Stocks That Hit 52-Week Lows On Thursday
· 27 Şub 2020
-
Stocks That Hit 52-Week Lows On Wednesday
· 26 Şub 2020
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
EMHTF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
EMHTF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, EMHTF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
EMHTF OTC Piyasa Bilgileri
The OTC Other tier, where EMHTF trades, represents the lowest tier of the OTC market. Companies in this tier often face challenges in meeting minimum financial standards required for higher exchanges like NYSE or NASDAQ. These companies may be experiencing financial distress, be in early stages of development, or have chosen to remain private but still allow trading of their securities. Investing in companies on the OTC Other tier carries significant risks due to the lack of stringent listing requirements and oversight compared to major exchanges.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited Liquidity: Low trading volumes and wide bid-ask spreads can make it difficult to buy or sell shares.
- Lack of Transparency: Unknown disclosure status raises concerns about the availability of financial information.
- Financial Distress: The company's negative profit and gross margins suggest potential financial challenges.
- Regulatory Risks: OTC-listed companies are subject to less regulatory oversight compared to major exchanges.
- Volatility: OTC stocks are often more volatile than those listed on major exchanges.
- Verify the availability of financial reports and other relevant information.
- Assess the company's financial health and operational performance.
- Evaluate the company's management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volumes and bid-ask spreads.
- Consult with a financial advisor before making any investment decisions.
- Operation as a subsidiary of Skye Bioscience, Inc.
- Established brands such as SYNC Wellness and Emerald.
- Distribution network within the Canadian cannabis market.
- Engagement in the regulated cannabis industry in Canada.
EMHTF Hakkında Sıkça Sorulan Sorular
EMHTF için değerlendirilmesi gereken temel faktörler nelerdir?
Emerald Health Therapeutics, Inc. (EMHTF) şu anda yapay zeka skoru 40/100, düşük puanı gösteriyor. Temel güçlü yan: Diverse product portfolio including dried cannabis, pre-rolls, oral sprays, and oils.. İzlenmesi gereken birincil risk: Ongoing: Oversupply and price compression in the Canadian cannabis market.. Bu bir finansal tavsiye değildir.
EMHTF MoonshotScore'u nedir?
EMHTF şu anda MoonshotScore'da 40/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
EMHTF verileri ne sıklıkla güncellenir?
EMHTF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler EMHTF hakkında ne diyor?
EMHTF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
EMHTF'a yatırım yapmanın riskleri nelerdir?
EMHTF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Ongoing: Oversupply and price compression in the Canadian cannabis market.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
EMHTF'ın P/E oranı nedir?
EMHTF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için EMHTF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
EMHTF aşırı değerli mi, yoksa düşük değerli mi?
Emerald Health Therapeutics, Inc. (EMHTF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
EMHTF'ın temettü verimi nedir?
Emerald Health Therapeutics, Inc. (EMHTF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Financial data is based on the most recent available information.
- OTC market data may be limited or less reliable than data from major exchanges.
- AI analysis is pending and may provide further insights.